Feb 18,2021

London-based AI startup Vinehealth secures £1M to empower cancer patients self-manage their life during treatment

Vinehealth, a London-based AI platform that aims to improve the quality of life and survival of cancer patients, has secured a �1 million Biomedical Catalyst grant. The funding will be used to improve cancer patient self-management and data collection across the UK healthcare system.

FUNDING GRANT
View Analyst & Ambassador Comments
Go to original news
Mar 03,2021

Blue Note Therapeutics Raises $26.25 Million in Series A Financing

Blue Note Therapeutics, Inc., today announced the closing of a Series A financing round of $26.25 million. Proceeds will allow the company to scale the organization and fund near-term clinical trials of its lead prescription digital therapeutic (PDT), which will potentially improve the treatment of cancer. The capital will also support the development of Blue Note's pipeline assets. The Series A financing was led by JAZZ Venture Partners and joined by Summer VC.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Mar 12,2021

Jasper Health Launches Comprehensive Support Platform for Individuals With Cancer and Their Caregivers

As part of the launch, Jasper raised $6.75 million in seed funding, co-led by 7wireVentures and Redesign Health, allowing the company to continue its deep support for Members and caregivers, and build out the expansion of its offering to provide services for partners in the healthcare system. 7wireVentures co-founder and Managing Partner Lee Shapiro also joins Jasper�s board of directors.

FUNDING SEED ROUND
View Analyst & Ambassador Comments
Go to original news
Mar 18,2021

Digital therapy support provider Mika closes funding round

The Berlin-based health start-up Fosanis, provider of the Mika app, has successfully closed another round of funding. Investors are Ananda Impact Ventures, Evodia and IBB Ventures. Fosanis will use the raised capital to further develop its product and to accelerate the distribution of the Mika app. In addition, Fosanis will advance the scientific studies on the effectiveness of Mika.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Mar 25,2021

Siemens Healthineers takes last major step in the Varian financing with placement of shares

Siemens Healthineers AG has successfully placed 53 million new shares with institutional investors through an accelerated book-building offering. The placement price was set at EUR 44.10 per share, resulting in gross proceeds of around EUR 2.34 billion before deduction of commissions and expenses. Approximately 16.2 percent of the offer size was allocated to Qatar Investment Authority (QIA). Thereby, the share capital of Siemens Healthineers AG will increase to EUR 1.128 billion. The new shares will be issued from authorized capital under exclusion of subscription rights of shareholders and will carry dividend rights as from October 1, 2020. Siemens Healthineers plans to use the net proceeds from the capital increase to partially finance the planned acquisition of Varian Medical Systems, Inc. (�Varian�).

FUNDING POST-IPO EQUITY
View Analyst & Ambassador Comments
Go to original news
Apr 20,2021

VieCure Announces $25 Million Series A Investment Led by Northpond Ventures to Improve Oncology Care, Scale A.I. and Patient-focused Technologies

VieCure, Inc. today announced the closing of its $25 million Series A growth equity investment, led by Northpond Ventures. An undisclosed investor is also contributing to the round. VieCure, an oncology clinical informatics company with an artificial intelligence (AI) enabled clinical decision support platform, will use the new funding to accelerate the deployment of its next generation clinical decision support solution, and grow the sales and business development organization in response to the expanding pipeline and partnering opportunities in the life sciences arena. Andrea Jackson, Director for Northpond Ventures, will join the new VieCure Board of Directors.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Apr 22,2021

BGF invests $12m in virtual oncology business Entia

Entia, a medical technology business, which recently announced a commercial partnership with Pfizer UK, raised $12 million earlier in the year in a funding round co-led by UK growth capital investor, BGF and growth fund manager, Parkwalk, with participation from existing seed investor Sussex Place Ventures.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Apr 28,2021

Outcomes4Me Raises $12M in Series A Funding Round

Outcomes4Me Inc., a Cambridge, Mass.-based developer of an Artificial Intelligence (AI)-powered platform to empower cancer patients to navigate their care, raised $12m in Series A funding round.The round was led by Northpond Ventures, with participation from all existing investors, including Sierra Ventures, Asset Management Ventures, Merstal Ltd, IRA Capital, and others. Andrea Jackson, a Northpond Ventures Director, will join Outcomes4Me�s board. The company intends to use the funds to extend its platform beyond breast cancer to other cancers, grow the platform�s regulatory-grade dataset, and expand to more patients in Europe

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
May 11,2021

Huma raises $130 million financing to scale its digital health platform for better care and research

Huma Therapeutics Limited today announces the completion of its latest funding round with financing of approximately $130 million. The investment will scale Huma's modular platform which can power digital 'hospitals at home' nationally, and support the pharmaceutical and research industries to run the largest ever decentralized clinical trials. Leaps by Bayer and Hitachi Ventures led the Series C funding round, which also saw new strategic and financial investors become shareholders. Samsung Next, Sony Innovation Fund by IGV*, Unilever Ventures and HAT Technology & Innovation Fund by HAT, as well as individuals Nikesh Arora (former president of SoftBank) and Michael Diekmann (Chairman of Allianz) are also new shareholders.

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
May 18,2021

PathAI Announces Completion of $165 Million Financing for Advancing Medicine with AI-powered Pathology

PathAI, a global provider of artificial intelligence-powered technology for pathology, announced today the closing of its $165 million Series C financing. PathAI will deploy its new capital to accelerate product development while continuing to prioritize the improvement of patient outcomes with reliable AI-powered technology and meaningful collaboration with pharmaceutical and diagnostic partners. The funds will expand the PathAI product suite and commercial footprint to enhance the full lifecycle of the drug development process from translational and exploratory research to global commercialization. This Series C financing round was co-led by D1 Capital Partners and by Kaiser Permanente, one of America's leading health care providers and not-for-profit health plans. Other investors included General Atlantic, Tiger Global Management, 8VC, Adage, Biospring Partners, General Catalyst, KdT Ventures, Polaris Partners, Refactor Capital and strategic partners Bristol-Myers Squibb Company, Labcorp and Merck Global Health Innovation Fund (GHI).

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
Subscribe to FUNDING